InMed Pharmaceuticals Inc. has announced its financial results for the fiscal year ending June 30, 2025. The company reported sales of $4.9 million in its BayMedica segment, marking an increase of $0.34 million, or 8%, compared to the previous year. The net loss for the company was recorded at $8.2 million, compared to a net loss of $7.7 million for the previous fiscal year. Research and development expenses decreased to $2.9 million from $3.2 million in the previous year, while general and administrative expenses increased to $6.6 million from $5.8 million. The company maintains a cash position of $11.1 million, which it expects will support its pharmaceutical developments into the fourth quarter of calendar year 2026. Additionally, InMed continued to advance its pharmaceutical pipeline, particularly with the INM-901 program, which targets multiple biological pathways related to Alzheimer's disease. The company also reported progress in the development of INM-089 for the treatment of dry age-related macular degeneration.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 267483) on September 23, 2025, and is solely responsible for the information contained therein.
Comments